The structure marked A — a loculated, multi-septated pleural fluid collection — combined with purulent fluid, low pH (<7.20), low glucose (<40 mg/dL), and positive Gram stain represents the fibrinopurulent phase of parapneumonic effusion evolution, which defines pleural empyema (pus in the pleural space). According to the Andrews classification and BTS guidelines, this stage is characterized by bacterial invasion, frank pus, and fibrin deposition producing the loculations visible on ultrasound. Management mandates prompt tube thoracostomy drainage (image-guided small-bore catheter is as effective as large-bore for early disease) combined with broad-spectrum intravenous antibiotics covering Streptococcus pneumoniae, Staphylococcus aureus, and anaerobes (e.g., ceftriaxone + metronidazole or piperacillin-tazobactam). For loculated empyema not draining adequately, intrapleural fibrinolytic therapy (TPA 10 mg + DNase 5 mg twice daily for 3 days per the MIST2 regimen) significantly improves drainage and reduces surgical referral, making it a key consideration before escalating to VATS.
BTS pleural disease guidelines; MIST2 trial NEJM 2011; Andrews classification of parapneumonic effusion
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.